Table 3 Characteristics of secondary dissemination
Number of patients (%) | |||
|---|---|---|---|
Characteristics | Whole group | HGG | DIPG |
Median time from primary diagnosis to secondary dissemination | 8.2 months | 8.2 months | 7.2 months |
Parenchymal metastasis | (n=46) | (n=32) | (n=14) |
Supratentorial | 16 (34.8%) | 11 (34.4%) | 5 (35.7%) |
Supra-+infratentorial | 9 (19.6%) | 6 (18.8%) | 3 (21.4%) |
Infratentorial | 3 (6.5%) | 2 (6.3%) | 1 (7.1%) |
Spinal | 5 (10.9%) | 4 (12.5%) | 1 (7.1%) |
Cerebral+spinal | 3 (6.5%) | 0 | 3 (21.4%) |
Leptomeningeal dissemination | 10 (21.7%) | 9 (28.1%) | 1 (7.1%) |
Chemotherapy of disseminated disease | (n=30) | (n=22) | (n=8) |
Topotecan | 7 (23.3%) | 4 (18.2%) | 3 (38%) |
Temozolomide | 11 (36.7%) | 9 (40.9%) | 2 (25%) |
Valproic acid | 1 (3.3%) | 1 (4.5%) | 0 (0%) |
Other chemotherapy | 9 (30.0%) | 6 (27.3% | 3 (38%) |
No chemotherapy | 2 (6.7%) | 2 (9.1% | 0 ((0%) |
Irradiation of disseminated disease | 2 | 2 | 0 |
Second surgery of disseminated disease | ND | ND | ND |
No treatment of disseminated disease | 2 | 2 | 0 |
Median OS after diagnosis of secondary dissemination (months) | 3.2 | 3.1 | 3.6 |
